^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Talvey (talquetamab-tgvs)

    i
    Other names: JNJ-64407564, JNJ 64407564, JNJ-7564 , JNJ64407564, JNJ7564, JNJ 7564
    Company:
    Genmab, J&J
    Drug class:
    CD3 agonist, GPRC5D inhibitor
    Related drugs:
    25d
    MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=11, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    29d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Oct 2025 --> Apr 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
    P2, N=75, Recruiting, SCRI Development Innovations, LLC | Trial completion date: Mar 2026 --> Oct 2027 | Trial primary completion date: Feb 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    aMMbition: A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=10, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    2ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2027 --> Jan 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    2ms
    TRIMM-2: A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=290, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2025 --> Apr 2027
    Trial primary completion date
    |
    pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    2ms
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2030 --> Jun 2027
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    2ms
    A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed
    Trial completion
    |
    Talvey (talquetamab-tgvs)
    3ms
    REALiTEC: A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (clinicaltrials.gov)
    P=N/A, N=900, Recruiting, Janssen-Cilag Ltd. | N=600 --> 900 | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment change • Trial primary completion date
    |
    Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    3ms
    Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (clinicaltrials.gov)
    P2, N=20, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    clonoSEQ
    |
    lenalidomide • Talvey (talquetamab-tgvs)
    4ms
    MonumenTAL-5: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=0, Withdrawn, Janssen Research & Development, LLC | Trial completion date: Nov 2022 --> Oct 2024
    Trial completion date
    |
    Blenrep (belantamab mafodotin-blmf) • Talvey (talquetamab-tgvs)